Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change

Q3 Medicine
Surbhi Grover , Rohini Bhatia , Tara M. Friebel-Klingner , Anikie Mathoma , Peter Vuylsteke , Salman Khan , Tlotlo Ralefala , Leabaneng Tawe , Lisa Bazzett-Matabele , Barati Monare , Rebecca Luckett , Doreen Ramogola-Masire
{"title":"Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change","authors":"Surbhi Grover ,&nbsp;Rohini Bhatia ,&nbsp;Tara M. Friebel-Klingner ,&nbsp;Anikie Mathoma ,&nbsp;Peter Vuylsteke ,&nbsp;Salman Khan ,&nbsp;Tlotlo Ralefala ,&nbsp;Leabaneng Tawe ,&nbsp;Lisa Bazzett-Matabele ,&nbsp;Barati Monare ,&nbsp;Rebecca Luckett ,&nbsp;Doreen Ramogola-Masire","doi":"10.1016/j.ctarc.2023.100682","DOIUrl":null,"url":null,"abstract":"<div><p>Women living with HIV (WLWH) are at an increased risk of developing HPV-related high grade cervical dysplasia and cervical cancer. Prior World Health Organization (WHO) screening guidelines recommended starting screening at age 30. We assessed characteristics of women diagnosed with cervical cancer to further inform and refine screening guidelines. We prospectively enrolled women diagnosed with cervical cancer from January 2015 to March 2020 at two tertiary hospitals in Gaborone, Botswana. We performed chi-square and ANOVA analyses to evaluate the association between age upon diagnosis and HIV status, CD4 count, viral load, and other sociodemographic and clinical factors. Data were available for 1130 women who were diagnosed with cervical cancer and 69.3% were WLWH. The median age overall was 47.9 (IQR 41.2–59.1), 44.6 IQR: 39.8 – 50.9) among WLWH, and 61.2 (IQR 48.6–69.3) among women living without HIV. There were 1.3% of women aged &lt;30 years old, 19.1% were 30–39 and 37.2% were 40–49. Overall, 20.4% (<em>n</em> = 231) of cancers were in women &lt;40 years. Age of cervical cancer diagnosis is younger in countries with higher HIV prevalence, like Botswana. Approximately 20% of the patients presented with cancer at &lt;40 years of age and would have likely benefited from screening 10 years prior to cancer diagnosis to provide an opportunity for detection and treatment of pre-invasive disease.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/89/nihms-1876285.PMC9999385.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Women living with HIV (WLWH) are at an increased risk of developing HPV-related high grade cervical dysplasia and cervical cancer. Prior World Health Organization (WHO) screening guidelines recommended starting screening at age 30. We assessed characteristics of women diagnosed with cervical cancer to further inform and refine screening guidelines. We prospectively enrolled women diagnosed with cervical cancer from January 2015 to March 2020 at two tertiary hospitals in Gaborone, Botswana. We performed chi-square and ANOVA analyses to evaluate the association between age upon diagnosis and HIV status, CD4 count, viral load, and other sociodemographic and clinical factors. Data were available for 1130 women who were diagnosed with cervical cancer and 69.3% were WLWH. The median age overall was 47.9 (IQR 41.2–59.1), 44.6 IQR: 39.8 – 50.9) among WLWH, and 61.2 (IQR 48.6–69.3) among women living without HIV. There were 1.3% of women aged <30 years old, 19.1% were 30–39 and 37.2% were 40–49. Overall, 20.4% (n = 231) of cancers were in women <40 years. Age of cervical cancer diagnosis is younger in countries with higher HIV prevalence, like Botswana. Approximately 20% of the patients presented with cancer at <40 years of age and would have likely benefited from screening 10 years prior to cancer diagnosis to provide an opportunity for detection and treatment of pre-invasive disease.

Abstract Image

艾滋病毒流行国家的宫颈癌筛查:迫切呼吁改变指南
感染艾滋病毒(WLWH)的妇女患HPV相关的高级别宫颈发育不良和宫颈癌症的风险增加。先前的世界卫生组织(世界卫生组织)筛查指南建议从30岁开始筛查。我们评估了被诊断为癌症的女性的特征,以进一步了解和完善筛查指南。我们对2015年1月至2020年3月在博茨瓦纳哈博罗内的两家三级医院诊断为癌症的女性进行了前瞻性研究。我们进行了卡方和方差分析,以评估诊断时的年龄与HIV状态、CD4计数、病毒载量以及其他社会人口统计学和临床因素之间的关系。数据可用于1130名被诊断为宫颈癌症的女性,69.3%为WLWH。WLWH的总体中位年龄为47.9(IQR 41.2–59.1),44.6 IQR:39.8–50.9),未感染HIV的女性为61.2(IQR 48.6–69.3)。年龄<;30岁,30–39岁占19.1%,40–49岁占37.2%。总体而言,20.4%(n=231)的癌症发生在女性<;40年。在博茨瓦纳等艾滋病毒流行率较高的国家,宫颈癌症诊断年龄较年轻。大约20%的患者在<;40岁,可能受益于癌症诊断前10年的筛查,为侵袭前疾病的检测和治疗提供机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信